28.14
price down icon2.26%   -0.65
pre-market  プレマーケット:  28.65   0.51   +1.81%
loading
前日終値:
$28.79
開ける:
$28.69
24時間の取引高:
874.38K
Relative Volume:
0.85
時価総額:
$1.67B
収益:
$66.05M
当期純損益:
$-422.60M
株価収益率:
-3.8808
EPS:
-7.251
ネットキャッシュフロー:
$-384.73M
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
+5.31%
6か月 パフォーマンス:
+11.49%
1年 パフォーマンス:
-4.90%
1日の値動き範囲:
Value
$28.04
$29.10
1週間の範囲:
Value
$27.45
$29.10
52週間の値動き範囲:
Value
$22.24
$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1106)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
540
Name
Twitter
@AgiosPharma
Name
次回の収益日
2026-04-29
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
AGIO icon
AGIO
Agios Pharmaceuticals Inc
28.14 1.71B 66.05M -422.60M -384.73M -7.251
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 繰り返されました H.C. Wainwright Buy
2025-11-24 開始されました Truist Buy
2025-11-20 アップグレード Leerink Partners Market Perform → Outperform
2025-11-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
May 25, 2026

AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView

May 25, 2026
pulisher
May 25, 2026

Agios Pharmaceuticals Gains EU Approval for PYRUKYND in Adult Thalassaemia - World Business Outlook

May 25, 2026
pulisher
May 22, 2026

Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt - The Joplin Globe

May 22, 2026
pulisher
May 22, 2026

Agios Pharmaceuticals (AGIO) Secures EU Approval for PYRUKYND - GuruFocus

May 22, 2026
pulisher
May 22, 2026

EU approves mitapivat for thalassaemia treatment in adults - Investing.com UK

May 22, 2026
pulisher
May 22, 2026

EU approves mitapivat for thalassaemia treatment in adults By Investing.com - Investing.com Nigeria

May 22, 2026
pulisher
May 22, 2026

Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU - marketscreener.com

May 22, 2026
pulisher
May 22, 2026

Agios Gets EU Approval for Pyrukynd in Thalassemia - Moomoo

May 22, 2026
pulisher
May 22, 2026

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - standard-journal.com

May 22, 2026
pulisher
May 22, 2026

New oral thalassemia drug PYRUKYND approved for adults in EU - Stock Titan

May 22, 2026
pulisher
May 22, 2026

Agios' Pyrukynd® (mitapivat) approved in the European Union for adults with thalassemia - marketscreener.com

May 22, 2026
pulisher
May 22, 2026

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - The Manila Times

May 22, 2026
pulisher
May 22, 2026

Agios Pharmaceuticals Receives EU Approval for PYRUKYND® as First Medicine for Thalassemia Treatment in Adults - Quiver Quantitative

May 22, 2026
pulisher
May 22, 2026

(AGIO) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 22, 2026
pulisher
May 19, 2026

Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Agios Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 19, 2026
pulisher
May 17, 2026

AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN

May 17, 2026
pulisher
May 17, 2026

Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN

May 17, 2026
pulisher
May 17, 2026

Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN

May 17, 2026
pulisher
May 16, 2026

How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease - Sahm

May 16, 2026
pulisher
May 15, 2026

Armistice Capital (NASDAQ: AGIO) holds 2.716M shares, 4.57% stake - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance

May 15, 2026
pulisher
May 15, 2026

How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance

May 15, 2026
pulisher
May 14, 2026

Developer seeking FDA’s accelerated approval for mitapivat for SCD - Sickle Cell Disease News

May 14, 2026
pulisher
May 14, 2026

TradingKey - TradingKey

May 14, 2026
pulisher
May 13, 2026

Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance

May 13, 2026
pulisher
May 13, 2026

Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - The Globe and Mail

May 13, 2026
pulisher
May 13, 2026

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $41 - Moomoo

May 13, 2026
pulisher
May 12, 2026

Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus

May 12, 2026
pulisher
May 12, 2026

Agios submits application for mitapivat in sickle cell disease - Investing.com UK

May 12, 2026
pulisher
May 12, 2026

Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia

May 12, 2026
pulisher
May 12, 2026

Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Australia

May 12, 2026
pulisher
May 12, 2026

Agios presents mitapivat data at European hematology congress - Investing.com

May 12, 2026
pulisher
May 12, 2026

Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative

May 12, 2026
pulisher
May 12, 2026

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times

May 12, 2026
pulisher
May 12, 2026

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times

May 12, 2026
pulisher
May 12, 2026

New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan

May 12, 2026
pulisher
May 12, 2026

Oral drug lifts hemoglobin in sickle cell and thalassemia trial - Stock Titan

May 12, 2026
pulisher
May 11, 2026

Price-Driven Insight from (AGIO) for Rule-Based Strategy - Stock Traders Daily

May 11, 2026
pulisher
May 11, 2026

47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D - MarketBeat

May 11, 2026
pulisher
May 09, 2026

Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView

May 09, 2026
pulisher
May 06, 2026

Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan

May 06, 2026
pulisher
May 04, 2026

Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛

May 04, 2026
pulisher
May 03, 2026

Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox

May 03, 2026
pulisher
May 03, 2026

Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm

May 03, 2026
pulisher
May 02, 2026

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - Yahoo Finance

May 02, 2026

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Burns James William
Chief Legal Officer
Apr 02 '26
Sale
34.71
3,280
113,849
49,306
Gheuens Sarah
Chief Medical Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
83,217
Gheuens Sarah
Chief Medical Officer
Apr 02 '26
Sale
34.71
2,940
102,047
80,277
Jones Cecilia
Chief Financial Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
58,139
Jones Cecilia
Chief Financial Officer
Apr 02 '26
Sale
34.71
3,141
109,024
54,998
Milanova Tsveta
Chief Commercial Officer
Apr 02 '26
Option Exercise
0.00
8,500
0
50,091
Milanova Tsveta
Chief Commercial Officer
Apr 02 '26
Sale
34.71
3,262
113,224
46,829
Viswanadhan Krishnan
Chief Corp Dev & Strategy
Apr 02 '26
Option Exercise
0.00
8,100
0
13,241
Viswanadhan Krishnan
Chief Corp Dev & Strategy
Apr 02 '26
Sale
34.71
2,959
102,707
10,282
Goff Brian
Chief Executive Officer
Apr 02 '26
Option Exercise
0.00
39,028
0
191,104
$29.96
price down icon 2.98%
$106.24
price down icon 3.00%
$92.14
price up icon 1.33%
$54.50
price up icon 1.77%
ONC ONC
$310.25
price up icon 0.20%
$151.56
price down icon 1.41%
大文字化:     |  ボリューム (24 時間):